PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

Deletion of C3 and C3aR reversed <i>S. aureus</i>-induced decrease in synapse density and increase in microglial phagocytosis of synapses. by Haifang Zhang (314544)

The sagittal view of T2-weighted Magnetic Resonance Imaging represented mild decreased spinal cord diameter without any other lesions at second admission. by Hossein Pourmontaseri (19329565)

National (A) Medicare prescription rates per thousand Part D enrollees and (B) Medicare spending for clozapine gradually decreased for 2015-2020. by Luke R. Cavanah (19022435)

Subjects:

Effects of busulfan treatment on the ultrastructure of the blood-testis barrier (BTB). by Lingjun Zhao (21763122)

Subjects:

Negative (Prednisone) and basal (ATP) control compounds binding to ALK protein. by Richard Junior Zapata Dongo (17912565)

Subjects:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

Probability of Cost-Effectiveness Across CET. by Yiping An (20609789)

Subjects:

Base-case analysis. by Yiping An (20609789)

Subjects:

Cost-effectiveness acceptability curve. by Yiping An (20609789)

Subjects:

Markov model. by Yiping An (20609789)

Subjects:

Incremental cost-effectiveness scatter plot. by Yiping An (20609789)

Subjects:

One-way sensitivity analysis. by Yiping An (20609789)

Subjects:

ICER changes with time horizon. by Yiping An (20609789)

Subjects: